Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prophylactic treatment of gram‐positive and gram‐negative abdominal implant infections using locally delivered polyclonal antibodies

Poelstra, Kornelis A., Barekzi, Nazir A., Rediske, Andrea M., Felts, Adrian G., Slunt, Jeffrey B., Grainger, David W.·2002·Journal of Biomedical Materials Research

Abstract

The increasing clinical incidence and host risk of biomaterial‐centered infections, as well as the reduced effectiveness of clinically relevant antibiotics to treat such infections, provide compelling reasons to develop new approaches for treating implanted biomaterials in a surgical context. We describe the direct local delivery of polyclonal human antibodies to abdominal surgical implant sites to reduce infection severity and mortality in a lethal murine model of surgical implant‐centered peritoneal infection. Surgical implant‐centered peritonitis was produced in 180 female CF‐1 mice by the direct inoculation of surgical‐grade polypropylene mesh disks placed in the peritoneal cavity with lethal doses of either methicillin‐resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa. Mice randomly received a resorbable antibody delivery vehicle at the implant site: either a blank carboxymethylcellulose (CMC) aqueous gel or the same CMC gel containing 10 mg of pooled polyclonal human immunoglobulin G locally on the implant after infection, either alone or in combination with systemic doses of cefazolin or vancomycin antibiotics. Human antibodies were rapidly released (first‐order kinetics) from the gel carrier to both peritoneal fluids and serum in both infection scenarios. Inocula required for lethal infection were substantially reduced by surgery and the presence of the implant versus a closed lethal peritonitis model. Survival to 10 days with two different gram‐negative P. aeruginosa strains was significantly enhanced (p < 0.01) by the direct application of CMC gel containing antibodies alone to the surgical implant site. Human‐equivalent doses of systemic vancomycin provided a significantly improved benefit (p < 0.01) against lethal, implant‐centered, gram‐positive MRSA infection. However, locally delivered polyclonal human antibodies in combination with a range of systemic vancomycin doses against MRSA failed to improve host survival. Successful antibody therapy against gram‐negative, implant‐centered infections complements the clinically routine use of systemic antibiotics, providing a mechanism of protection independent of antibiotic resistance. © 2002 Wiley Periodicals, Inc. J Biomed Mater Res 60: 206–215, 2002

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbm.10069

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 158

Metadata

Authors
Poelstra, K. A., Barekzi, N. A., Rediske, A. M., Felts, A. G., Slunt, J. B., & Grainger, D. W.
Venue
Journal of Biomedical Materials Research
Publisher
Wiley
Published
2002-01-23
Volume
60
Issue
1
Pages
206-215
ISSN
  • 0021-9304 (ISSN-L)
  • 1097-4636
OpenAlex
W1984454581
Cited by
158
References
1
FWCI
3.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prophylactic treatment of gram‐positive and gram‐negative abdominal implant infections using locally delivered polyclonal antibodies. https://app.cochat.ai/papers/10.1002/jbm.10069
The paper
Poelstra, K. A., Barekzi, N. A., Rediske, A. M., Felts, A. G., Slunt, J. B., & Grainger, D. W. (2002). Prophylactic treatment of gram‐positive and gram‐negative abdominal implant infections using locally delivered polyclonal antibodies. Journal of Biomedical Materials Research. https://doi.org/10.1002/jbm.10069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.